Cargando…
Understanding the mechanisms of aromatase inhibitor resistance
Aromatase inhibitors (AIs) have a central role in the treatment of breast cancer; however, resistance is a major obstacle to optimal management. Evidence from endocrine, molecular and pathological measurements in clinical material taken before and after therapy with AIs and data from clinical trials...
Autores principales: | Miller, William R, Larionov, Alexey A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496110/ https://www.ncbi.nlm.nih.gov/pubmed/22277572 http://dx.doi.org/10.1186/bcr2931 |
Ejemplares similares
-
Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole
por: Miller, William R, et al.
Publicado: (2010) -
Aromatase 2004, Edinburgh, UK, 6-8 September 2004
por: Miller, William R, et al.
Publicado: (2005) -
Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007) -
Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
por: Hyder, Tara, et al.
Publicado: (2021) -
Mechanisms of allosteric and mixed mode aromatase inhibitors
por: Souza, Samson A., et al.
Publicado: (2021)